How to Buy Bridgebio Oncology Therapeutics Stock
Bridgebio Oncology Therapeutics Inc
BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing next-generation small molecule therapeutics targeting RAS and PI3Kα malignancies, which are prevalent oncogenes in human tumors.
Bridgebio Oncology Therapeutics stock last closed at $9.22, down 1.81% from the previous day, and has decreased 14.55% in one year. It has underperformed other stocks in the Biotechnology industry by 0.06 percentage points. Bridgebio Oncology Therapeutics stock is currently +14.11% from its 52-week low of $8.08, and -38% from its 52-week high of $14.87.
There are currently 80.03M BBOT shares outstanding. The market cap of BBOT is $737.90M. In the past 24 hours, 244,000 BBOT shares were traded.
How to Buy Bridgebio Oncology Therapeutics Stock
Wondering how to invest in Bridgebio Oncology Therapeutics stock? Here's how.
- Choose where to buy Bridgebio Oncology Therapeutics stock: You need to pick an online brokerage, but don't worry - we've sifted through dozens of stock brokerages and apps to help you choose where to buy Bridgebio Oncology Therapeutics stock.
- Create a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found.
- Fund your brokerage account: Pick your payment method and add your details.
- Research Bridgebio Oncology Therapeutics stock: The Bridgebio Oncology Therapeutics ticker symbol is BBOT. Is Bridgebio Oncology Therapeutics stock a good investment? Should you buy shares of BBOT? How do BBOT's underlying business fundamentals look? Do top analysts think Bridgebio Oncology Therapeutics is a good buy? Why has BBOT's stock price moved recently? (Hint: Our stock research tools can help you decide if BBOT is a good stock to buy).
- Place your BBOT purchase: Decide if you will purchase BBOT shares at the current market price or use a limit order to purchase BBOT shares at a given price.
- Get the latest news on your investment in BBOT: Create a watchlist to get live updates on your new investment in Bridgebio Oncology Therapeutics shares.
Step 1: Choose where to buy Bridgebio Oncology Therapeutics stock
You need an online brokerage account to access the NASDAQ market and buy BBOT shares.
Our recommended brokerage: eToro
Based on our experience, eToro is the best stock brokerage. eToro gives you:
- You can invest in stocks with zero commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still invest in the stock.
- Access to world financial markets: From Technology to Financial Services, New York to Hong Kong (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's leading exchanges.
- Social investing: eToro boasts a community with more than 20 million users globally. Talk to, learn from, and copy the unique crypto portfolios of top investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other assets: Such as ETFs and cryptocurrencies.
Get $10 towards your purchase of shares by creating an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Create a brokerage account
Now that you've picked your brokerage, the next step is to fill out some personal info so you can buy BBOT stock today.
How to Start a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal data to create your new brokerage account.
- Submit your application by hitting the "Create Account" button. Get started with eToro today
Step 3: Fund your brokerage account
Now that you've created your account on mobile trading apps, your next step is to transfer the money for your investment:
Check out this video walkthrough if you need help depositing money into your investment account.
Step 4: Research Bridgebio Oncology Therapeutics stock
After you have selected the best place to buy Bridgebio Oncology Therapeutics stock, it's absolutely critical to evaluate their stock prior to investing, so you can understand the risk and opportunity.
Bridgebio Oncology Therapeutics Numbers
Bridgebio Oncology Therapeutics Due Diligence Checks
WallStreetZen was created to help part-time investors perform more in-depth fundamental analysis quickly.
You can see all of the due diligence checks on BBOT's stock page.
Is BBOT stock properly valued?
You can use a variety of different financial metrics, analyses, models, and charts to gauge BBOT's fair value.
Using relative valuations ratios:
- BBOT may be undervalued based on its P/B ratio of 1.79x, relative to Biotechnology industry P/B ratio of 5.02x
You can do additional valuation research on BBOT's stock here.
How do BBOT Financials look?
Passed Financial Due Diligence Checks:
- BBOT has $425.59M in cash and short term investments. This is enough to cover its annual cash burn of $114.50M.
- BBOT has a low debt to equity ratio of 0.09.
- BBOT has cash burn of 114500000. It has sufficient cash and short-term investments to cover this for at least one year.
- There are more short-term assets than long-term liabilities on the BBOT balance sheet.
- There are more short-term assets than short-term liabilities on the BBOT balance sheet.
Is Bridgebio Oncology Therapeutics stock a Buy, Hold, or Sell, according to Wall Street analysts?
Out of 6 Equities analysts who monitor BBOT, the consensus analyst rating on Bridgebio Oncology Therapeutics is a Strong Buy
Please note that analyst ratings are not stock recommendations, nor are they investment advice.
Most Recent BBOT Analyst Ratings
Matthew Biegler, a bottom 9% analyst from Oppenheimer maintains BBOT with a buy rating and lowers their BBOT price target from $23.00 to $22.00, on Nov 13, 2025.
You can dive deeper into what analysts are projecting on the Bridgebio Oncology Therapeutics stock forecast page.
BBOT Technical Indicators
Are BBOT insiders buying or selling the stock?
Over the past year, insiders at BBOT have bought more shares than they have sold.
Bihua Chen, Director of BBOT, was the latest BBOT insider to buy. They bought $8,150,235.63 worth of BBOT stock on Aug 11, 2025.
Research more about who owns BBOT shares here.
Does BBOT stock generate passive income?
No, Bridgebio Oncology Therapeutics doesn't provide an income stream by paying out dividends.
What others are saying about BBOT
One of the primary reasons eToro is our favorite brokerage is because of its social trading community.
Click below to see what other community members have to say.
Step 5: Place your BBOT purchase
There are two primary order types:
- Market order: A market order is an order to buy or sell a stock at the best price on the market.
Market orders are mostly sufficient. - Limit order: A limit order enables you to buy or sell a security at a specific price (or better).
If you want to ensure you're buying or selling at a specific dollar amount limit, place a limit order.
Hit the Open button and eToro will place your order.
If you require additional help with buying stocks on eToro, click the helpful video below:
Step 6: Get the latest news on your investment in BBOT
Now that you own some BBOT stock, you'll want to keep up with your new investment.
Create a watchlist to monitor your BBOT stock.
BBOT Feed
How to Buy Stock in Bridgebio Oncology Therapeutics
To summarize, here are the 6 steps you need to take to buy Bridgebio Oncology Therapeutics stock right now:
- Choose where to buy Bridgebio Oncology Therapeutics stock
- Create a brokerage account
- Fund your brokerage account
- Research Bridgebio Oncology Therapeutics stock
- Place your BBOT purchase
- Get the latest news on your investment in BBOT
If you are looking for a place to buy stocks, eToro is our favorite venue.
Get Started with eToro TodayIf you want to keep an eye on your investment in Bridgebio Oncology Therapeutics, create a watchlist today.
More Stock Buying Guides You May Find Useful
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.